Please sign in to follow a disease.
Can a Parkinson's drug boost brain function in depressed seniors?
NCT ID NCT04469959
First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 3 times
Summary
This study tested whether levodopa, a drug used for Parkinson's disease, can improve thinking speed, walking, and mood in older adults with depression. Researchers gave 79 participants either levodopa or a placebo for three weeks. The goal was to see if boosting dopamine could help with the mental and physical slowing often seen in late-life depression.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Levodopa (carbidopa/levodopa, also known as Sinemet)
- What this could lead to
- If it works, this could point toward a treatment that improves thinking speed and mobility in older adults with depression.
- What could go wrong
- This is a small, early-phase trial with only 79 participants. The treatment is short-term, and benefits may not last or apply to everyone. Levodopa can cause side effects like nausea or dizziness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
79 people
The number who actually took part.
- Started
-
Feb 2021
- Finished
-
Apr 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
60 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age ≥ 60 years 2. Diagnostic and Statistical Manual-5 (DSM5) diagnosis of Major Depressive Disorder, Persistent Depressive Disorder, or Depression Not Otherwise Specified (NOS) 3. MADRS score ≥ 15 4. Decreased processing speed (0.5 SD below age-adjusted norms on the WAIS-IV Coding task or Trail Making Test, Part A) or decreased motor speed (gait speed/average walking speed on 15' course ≤ 1m/s, or 0.5 SD below age-, gender- and education-adjusted norms on the grooved pegboard test) 5. Capable of providing informed consent and adhering to study procedures Exclusion Criteria: 1. Diagnosis of substance abuse or dependence (excluding Tobacco Use Disorder) in the past 12 months 2. Other psychiatric disorders including a history of psychosis, psychotic disorder, mania, or bipolar disorder. Other comorbid psychiatric disorders are allowable if the depressive disorder diagnosis is considered to be the primary problem 3. Primary neurological disorder, including dementia, stroke, Parkinson's disease, epilepsy, etc 4. SBT \> 10 5. MADRS suicide item \> 4 or other indication of acute suicidality 6. History of inpatient psychiatric hospitalization in the last year; 7. History of suicidal ideation in the last 6 months, operationalized as a 'yes' response to item 4 or 5 in the "Suicidal Ideation" section of the Columbia-Suicide Severity Rating Scale (CSSRS) 8. Any suicidal behavior in the last year (operationalized as a 'yes' response to any item in the "Suicidal Behavior" section of the CSSRS, including actual interrupted, aborted, or preparatory acts) 9. Current or recent (within the past 2 weeks) treatment with antipsychotics or mood stabilizers, or use of antidepressants where washout is not advisable 10. History of hypersensitivity, allergy, or intolerance to Carbidopa/levodopa 11. Any physical or intellectual disability adversely affecting ability to complete assessments 12. Unstable medical illness 13. Mobility limiting osteoarthritis of any lower extremity joints, symptomatic lumbar spine disease, or history of joint replacement / spine surgery that limits mobility 14. Diagnosis of HIV 15. History of significant radioactivity exposure (nuclear medicine studies or occupational exposure).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cognitive decline are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States
-
Vanderbilt Psychiatric Hospital
Nashville, Tennessee, 37212, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Brain-Signaling drug crack depression that resists standard treatment?
- Can a daily supplement shield the brain after delirium?
- A brain stimulation trial aims to rewire the circuit behind depression
- App-Based lifestyle coaching aims to cut dementia risk in older adults
- Brain scans may reveal hidden subtypes of Late-Life depression
- Can diet and lifestyle shape life after a heart attack? a large study investigates